In Brief: Tri-Point Medical
This article was originally published in The Gray Sheet
Executive Summary
Tri-Point Medical: Files premarket approval application with FDA for its TraumaSeal topical tissue cohesion product. TraumaSeal is intended as an alternative to surgical sutures or staples in closing wounds "caused by skin lacerations and incisions, minimally invasive surgery, and plastic surgery," Tri-Point says. The product has been granted expedited review status by FDA. In March, the Raleigh, North Carolina firm entered an exclusive worldwide marketing agreement for the product with Johnson & Johnson's Ethicon division ("The Gray Sheet" April 1, In Brief)...